Myriad Enters Cancer Monitoring Race with Ultrasensitive MRD Test

SALT LAKE CITY, UT – January 27, 2026 – Myriad Genetics, a long-standing leader in molecular diagnostics, has announced it will commercially launch its highly anticipated Precise MRD™ assay in March, marking a significant entry into the rapidly evolving field of cancer surveillance. The move, bolstered by compelling new clinical data, positions the company to compete in the multi-billion dollar market for molecular residual disease (MRD) testing, a technology poised to redefine how doctors and patients manage cancer after initial treatment.

The test, which detects trace amounts of circulating tumor DNA (ctDNA) in the bloodstream, will first be available for breast cancer patients through select clinicians, with plans to expand to colorectal and renal cancers later in 2026. This phased rollout signals a deliberate strategy to establish a foothold in a market that promises earlier recurrence detection, more personalized treatment decisions, and a new sense of clarity for millions of cancer survivors.

“Our Precise MRD program reflects Myriad’s unwavering commitment to advancing precision oncology by bringing ultrasensitive MRD testing into real-world clinical care,” said Sam Raha, President and CEO, Myriad Genetics, in a statement. He added that the launch represents "meaningful progress toward earlier insight, more informed decisions, and better outcomes for patients.”

The Power of Ultrasensitive Detection

At the heart of Myriad's announcement is the technology behind Precise MRD. It is a tumor-informed, whole-genome sequencing (WGS) assay. This process involves first sequencing a patient's primary tumor to create a unique "fingerprint" of up to 1,000 specific mutations. The liquid biopsy test then uses this personalized signature to hunt for ctDNA in the blood with extreme sensitivity, capable of detecting as little as one cancerous part-per-million (ppm).

This ultrasensitive capability is not just a technical benchmark; it has profound clinical implications, as highlighted by recent studies. In the MONITOR-Breast study, results presented at the 2025 San Antonio Breast Cancer Symposium showed the test had a 93% baseline sensitivity in Stage I-III breast cancer patients. Crucially, it demonstrated that the clearance of ctDNA by day 50 of pre-surgical therapy was a strong predictor of a complete response to treatment. Conversely, even intermittent or low-level ctDNA positivity was significantly associated with residual disease.

Perhaps most notably, the study found that 73% of ctDNA-positive samples after neoadjuvant therapy were detected at levels below 100 ppm—a range often below the detection threshold of first-generation assays. This suggests Precise MRD can identify patients at high risk of recurrence who might otherwise be missed. Similar powerful results came from the MONSTAR-SCREEN-3 study in colorectal cancer, which reported 100% baseline ctDNA detection and 100% sensitivity in predicting recurrence one month after surgery.

Entering a Crowded and Competitive Field

While the clinical data is promising, Myriad is entering a fiercely competitive landscape. The MRD testing market, valued at over $2 billion in 2023, is projected to more than double within the next decade, attracting numerous well-established players and innovative startups. The dominant force is currently Natera, whose Signatera test holds an estimated 80% of the market share for MRD detection in solid tumors. Like Myriad's test, Signatera is a tumor-informed assay celebrated for its high sensitivity and supported by extensive clinical evidence and growing payer coverage.

Another major competitor is Guardant Health, whose Guardant Reveal test utilizes a tumor-agnostic approach. This method uses a pre-set panel to screen for common cancer mutations directly from blood, bypassing the need for an initial tumor tissue sample. This offers faster turnaround and broader accessibility, though historically it has come with a trade-off in sensitivity compared to personalized, tumor-informed methods.

Myriad’s strategy appears to be a direct challenge to Natera, competing on the grounds of sensitivity and robust clinical validation. The company is leveraging its long-standing relationships in oncology and bolstering its evidence base through a five-year strategic alliance with the prestigious MD Anderson Cancer Center. This collaboration aims to generate the data necessary to support inclusion in national treatment guidelines, a critical step for widespread clinical adoption.

The Hurdles of Adoption and Reimbursement

A groundbreaking test is only as valuable as its accessibility, and Myriad faces two significant hurdles: clinical adoption and insurance reimbursement. While oncologists are increasingly recognizing MRD as a powerful prognostic tool, its use is not yet standard practice across all cancer types. Professional bodies like the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) are cautiously integrating ctDNA testing into guidelines as evidence mounts. The landmark DYNAMIC study, which showed that MRD testing could successfully guide adjuvant chemotherapy decisions in Stage II colon cancer, set a vital precedent for proving clinical utility, a benchmark Myriad will also need to meet.

The reimbursement landscape is even more complex. While Medicare and private payers have begun to cover ctDNA tests for initial treatment selection, coverage for MRD surveillance after treatment remains inconsistent. Gaining broad payer approval will require Myriad to demonstrate not only that Precise MRD improves patient outcomes but also that it is cost-effective. The argument is compelling: by identifying patients who can safely forgo toxic adjuvant chemotherapy or by catching recurrence early enough for less intensive intervention, the test could generate significant healthcare savings.

Adding another layer of complexity is the FDA's new rule on laboratory-developed tests (LDTs), which will phase in greater regulatory oversight. While this aims to ensure test safety and efficacy, it will also increase compliance burdens and could influence the path to market and reimbursement for new assays like Precise MRD.

A New Outlook for Cancer Survivors

Beyond the market dynamics and regulatory challenges lies the profound potential impact on patient lives. For millions of cancer survivors, life after treatment is often shadowed by the fear of recurrence, a state of anxiety punctuated by periodic scans. Ultrasensitive MRD testing offers a new paradigm of surveillance that could transform this experience.

A negative test result can provide a level of reassurance and peace of mind that was previously unattainable. Conversely, a positive result, while difficult news, provides an invaluable early warning. Detecting recurrence months or even years before it becomes visible on a CT scan opens a critical window for intervention, potentially with more effective and less aggressive therapies.

This technology is a cornerstone of personalized medicine. It empowers physicians to de-escalate treatment for patients with a negative MRD test, sparing them from unnecessary toxicity and side effects. For those who test positive, it provides a clear rationale for intensifying therapy or enrolling in clinical trials for novel treatments. This dynamic risk stratification promises to move cancer care away from a one-size-fits-all approach and toward a future where treatment is continuously tailored to the individual patient's molecular reality. As tests like Precise MRD become more integrated into clinical practice, they offer not just a way to monitor disease, but a new sense of control and hope on the long journey of cancer survivorship.